This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Vical
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier:
NCT01877655
First received: June 12, 2013
Last updated: May 26, 2017
Last verified: May 2017
  Purpose
The purpose of the study is to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in subjects undergoing allogeneic HCT will also be evaluated.

Condition Intervention Phase
Cytomegalovirus (CMV)-Positive Recipients Allogeneic, Hematopoietic Cell Transplant (HCT) Biological: ASP0113 Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Further study details as provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):

Primary Outcome Measures:
  • Composite of overall mortality and cytomegalovirus (CMV) End Organ Disease (EOD) through one year post-transplant [ Time Frame: One year post-transplant ]

Secondary Outcome Measures:
  • Time to first protocol-defined CMV viremia [ Time Frame: One year post transplant ]
    CMV viremia defined as CMV plasma viral load ≥ 1000 IU/mL as assessed by the central laboratory

  • Time to first adjudicated CMV-specific anti-viral therapy (AVT) [ Time Frame: One year post-transplant ]
  • Time to first CMV-specific AVT for protocol-defined CMV viremia or CMV EOD [ Time Frame: One year post-transplant ]
    CMV viremia defined as CMV plasma viral load ≥ 1000 IU/mL as assessed by the central laboratory


Enrollment: 514
Actual Study Start Date: September 22, 2013
Estimated Study Completion Date: March 22, 2022
Estimated Primary Completion Date: October 16, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ASP0113
ASP0113 arm
Biological: ASP0113
intramuscular injection
Placebo Comparator: Placebo
Placebo arm
Drug: Placebo
intramuscular injection

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is a CMV-seropositive HCT recipient
  • Subject is planned to undergo either of the following:

    • Sibling Donor Transplant
    • Unrelated Donor Transplant
  • Subject has one of the following underlying diseases:

    • Acute myeloid leukemia (AML)
    • Acute lymphoblastic leukemia (ALL)
    • Acute undifferentiated leukemia (AUL)
    • Acute biphenotypic leukemia
    • Chronic myelogenous leukemia (CML)
    • Chronic lymphocytic leukemia (CLL).
    • A defined myelodysplastic syndrome(s) (MDS)
    • Primary or secondary myelofibrosis
    • Lymphoma (including Hodgkin's)

Exclusion Criteria:

  • Subject has active CMV disease or infection or has received treatment for active CMV disease or infection within 3 months (90 days) prior to transplant
  • Subject has a modified hematopoietic cell transplant comorbidity index (HCT-CI) score ≥ 4
  • Subject has received a prior HCT and has residual Chronic Graft-versus-host Disease (cGVHD)
  • Subject who is scheduled to have a cord blood transplant or a haploidentical transplant
  • Subject has a platelet count of less than 50,000 mm3 within 3 days prior to randomization (platelet transfusions are allowed)
  • Subject has aplastic anemia or multiple myeloma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01877655

  Show 83 Study Locations
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Vical
Investigators
Study Director: Medical Director Astellas Pharma Global Development, Inc.
  More Information

Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT01877655     History of Changes
Other Study ID Numbers: 0113-CL-1004
2013-000903-18 ( EudraCT Number )
Study First Received: June 12, 2013
Last Updated: May 26, 2017
Individual Participant Data  
Plan to Share IPD: Undecided
Plan Description: An investigational test is being used to measure the cytomegalovirus (CMV) viral load in the plasma.

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
ASP0113
Cytomegalovirus (CMV)
Hematopoietic Cell Transplant (HCT)

Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 26, 2017